Logo

Thomas Bachmann

Feb 02, 2015

Bruker BioSpin Group President Thomas Bachmann is resigning from Bruker, effective in July in order to become the president and CEO of the Eppendorf Group. He will remain president of Bruker BioSpin until the end of the second quarter and start his new position no later than Aug. 1, Bruker said in a document filed with the US Securities and Exchange Commission. Bruker will begin a search for his successor. Bachmann has been president of Bruker BioSpin since August 2013 and a member of Eppendorf's supervisory board since 2013.  

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.